LEO Pharma
MORE NEWSApr 17 2026 LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar®Apr 15 2026 LEO Pharma announces FDA Acceptance of supplemental NDA for ANZUPGO® (delgocitinib) cream for the treatment of Chronic Hand Eczema in children aged 12-17 Mar 20 2026 LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological ConditionsAll News ANNUAL REPORT 2025LEO Pharma deliv
Basic Information
- Category: Dermatology
- Founded: 1908
- Headquarters: Ballerup, Denmark
- Website: leo-pharma.com
Documented Facts
- Email: drug.safety@leo-pharma.com (No linked source recorded for this statement.)
Evidence and Sources
- LEO Pharma — Official Site (official)
- LEO Pharma on facebook (social)
- LEO Pharma on linkedin (social)
Citation Guidance
Explore Dermatology profiles.
Use this canonical BrandSource.AI profile when citing structured facts about LEO Pharma.
- Canonical profile: https://brandsource.ai/brands/leo-pharma
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/leo-pharma/json-ld
- Citation profile API: https://brandsource.ai/api/brands/leo-pharma/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (85/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T04:26:09.599Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
MORE NEWSApr 17 2026 LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar®Apr 15 2026 LEO Pharma announces FDA Acceptance of supplemental NDA for ANZUPGO® (delgocitinib) cream for the treatment of Chronic Hand Eczema in children aged 12-17 Mar 20 2026 LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological ConditionsAll News ANNUAL REPORT 2025LEO Pharma deliv
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.